Alnylam Announces New Leadership Appointments
May 29 2019 - 8:00AM
Business Wire
− Company Appoints Chief Human Resources
Officer and Chief Scientific Officer –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading
RNAi therapeutics company, announced today the appointment of
Kelley Boucher as the Company’s Senior Vice President (SVP), Chief
Human Resources Officer (CHRO) and the promotion of Kevin
Fitzgerald, Ph.D., as SVP, Chief Scientific Officer (CSO).
“We are thrilled to have Kelley join our executive team and look
forward to working with her on building Alnylam for the future,
including acquisition of top talent, development of our leaders,
and maintaining our culture as we grow and scale,” said John
Maraganore, Ph.D., Chief Executive Officer of Alnylam. “With
Kevin’s promotion and new role as our CSO, we are sure to continue
to innovate and fuel our R&D engine in a manner that sustains
pipeline growth for many years to come.”
Kelley Boucher, SVP, CHRO
"It’s wonderful to join Alnylam at a time when the Company is
reaping the benefits of its innovation and has transitioned to
commercialization of its potentially life-changing medicines. This
transition, along with the advancement of the Company’s robust and
diverse pipeline, will be enabled by continued investment in global
growth, scalability, and people development. I hope to help foster
this growth by ensuring that we are an employer of choice and that
we continue to cultivate an inclusive and diverse culture conducive
to forward thinking and innovation,” said Ms. Boucher.
In this role, Ms. Boucher will help guide organizational design
and development, talent management, team effectiveness, culture,
change management, and strategic talent acquisition – all while
ensuring that Alnylam culture and philosophy are scalable and
permeate the Company’s 26 current offices across 18 countries
around the world.
Ms. Boucher comes with over 15 years of human resources and
talent acquisition/management experience in the biotech sector.
Most recently, Ms. Boucher was the Vice President (VP) and Head of
Global Human Resources for Abiomed, a medical device company. Prior
to this, she was VP, Head of Human Resources for Corporate
Divisions at Shire Pharmaceuticals where she spent 10 years holding
multiple positions of increasing responsibility. Earlier in her
career, Ms. Boucher was a Principal Consultant for Clockwork
Consulting and held Human Resources roles at Syntonix
Pharmaceuticals and Digitas. Kelley holds a Bachelor of Arts,
Government Relations degree from Cornell University.
Kevin Fitzgerald, Ph.D., SVP, CSO
“It’s been a privilege to contribute to the growth of our rich
pipeline and our Company’s evolution, having pioneered the
translation of RNAi therapeutics from a Nobel Prize-winning
discovery to a new class of medicines with the potential to
transform the lives of thousands of underserved patients
worldwide,” said Dr. Fitzgerald. “I am very excited to lead the
discovery and development of the next wave of Alnylam’s RNAi
therapeutics.”
In his role, Dr. Fitzgerald will be responsible for the
strategic direction and oversight of Alnylam’s discovery engine. He
has over 20 years of experience in the context of small molecule
and oligonucleotide drug discovery. Dr. Fitzgerald’s tenure at
Alnylam began in 2005 when he joined as an Associate Director of
Research. He has headed the Research department since 2016. His
achievements include leadership of Alnylam’s RNAi delivery efforts,
resulting in two clinically validated modes of siRNA delivery, as
well as the development of the Company’s comprehensive clinical
pipeline. He is an inventor on over 50 patents that apply to the
majority of Alnylam’s pipeline programs, and the author of over 40
manuscripts, including many in prestigious journals such as Nature,
Cell, and The New England Journal of Medicine. Kevin has led or
supported multiple programs from discovery through various stages
of clinical development. Kevin received his Bachelor of Science in
Genetics from Cornell University and his doctorate in Molecular
Biology from Princeton University. He completed his post-doctoral
fellowship at Harvard Medical School.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class
of innovative medicines with the potential to transform the lives
of people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system/ocular diseases. Based on
Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of
diseases with high unmet need. ONPATTRO® (patisiran) is the
first-ever RNAi therapeutic approved by the U.S. FDA for the
treatment of the polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults and by the EMA
for the treatment of hATTR amyloidosis in adults with stage 1 or
stage 2 polyneuropathy. Alnylam has a deep pipeline of
investigational medicines, including six product candidates in
Phase 3 studies. Looking forward, Alnylam will continue to execute
on its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Headquartered in
Cambridge, MA, Alnylam employs over 1,200 people worldwide. For
more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at
@Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190529005089/en/
Alnylam Pharmaceuticals, Inc.Christine Regan
Lindenboom(Investors and Media)617-682-4340
Josh Brodsky(Investors)617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024